SciClone gets rights to APR's RapidFilm ondansetron
Executive Summary
SciClone Pharmaceuticals (cancer and infectious diseases) has licensed exclusive Chinese commercialization rights to APR Applied Pharma Research SA's (drug delivery and medical devices) RapidFilm formulation of the supportive oncology therapy ondansetron.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice